Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard C Strange

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
World Journal of Diabetes|March 17, 2016
Use of fibrates in the metabolic syndrome: A reviewKate E Shipman, Richard C Strange, Sudarshan Ramachandran
Expert Review of Anticancer Therapy|October 18, 2002
Environment, phenotype and genetics: risk factors associated with BCC of the skinPaul R Hoban, Sudarshan Ramachandran, Richard C Strange
Sexual Medicine Reviews|August 27, 2019
Sex Hormone Binding Globulin: A Review of its Interactions With Testosterone and Age, and its Impact on Mortality in Men With Type 2 DiabetesSudarshan Ramachandran, Geoffrey I Hackett, Richard C Strange
Andrology|May 9, 2020
Testosterone replacement therapy: Pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroupsSudarshan Ramachandran, Geoffrey I Hackett, Richard C Strange
World Journal of Diabetes|July 18, 2015
Metabolic syndrome: A review of the role of vitamin D in mediating susceptibility and outcomeRichard C Strange, Kate E Shipman, Sudarshan Ramachandran
Mutation Research|March 8, 2005
Ultraviolet radiation: effects on risks of prostate cancer and other internal cancersSamuel J Moon, Anthony A Fryer, Richard C Strange
Photochemistry and Photobiology|July 19, 2005
Ultraviolet radiation, vitamin D and risk of prostate cancer and other diseasesSamuel J Moon, Anthony A Fryer, Richard C Strange
World Journal of Diabetes|March 28, 2017
Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetesGeoffrey Hackett, Peter W Jones, Richard C Strange, et al.
Postgraduate Medical Journal|August 18, 2016
A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levelsCarl Groves, Chandrashekar Shetty, Richard C Strange, et al.
BJU International|September 15, 2018
Long-term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factorsGeoffrey Hackett, Nigel Cole, Akhilesh Mulay, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
World Journal of Diabetes|March 17, 2016
Use of fibrates in the metabolic syndrome: A reviewKate E Shipman, Richard C Strange, Sudarshan Ramachandran
Expert Review of Anticancer Therapy|October 18, 2002
Environment, phenotype and genetics: risk factors associated with BCC of the skinPaul R Hoban, Sudarshan Ramachandran, Richard C Strange
Sexual Medicine Reviews|August 27, 2019
Sex Hormone Binding Globulin: A Review of its Interactions With Testosterone and Age, and its Impact on Mortality in Men With Type 2 DiabetesSudarshan Ramachandran, Geoffrey I Hackett, Richard C Strange
Andrology|May 9, 2020
Testosterone replacement therapy: Pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroupsSudarshan Ramachandran, Geoffrey I Hackett, Richard C Strange
World Journal of Diabetes|July 18, 2015
Metabolic syndrome: A review of the role of vitamin D in mediating susceptibility and outcomeRichard C Strange, Kate E Shipman, Sudarshan Ramachandran
Mutation Research|March 8, 2005
Ultraviolet radiation: effects on risks of prostate cancer and other internal cancersSamuel J Moon, Anthony A Fryer, Richard C Strange
Photochemistry and Photobiology|July 19, 2005
Ultraviolet radiation, vitamin D and risk of prostate cancer and other diseasesSamuel J Moon, Anthony A Fryer, Richard C Strange
World Journal of Diabetes|March 28, 2017
Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetesGeoffrey Hackett, Peter W Jones, Richard C Strange, et al.
Postgraduate Medical Journal|August 18, 2016
A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levelsCarl Groves, Chandrashekar Shetty, Richard C Strange, et al.
BJU International|September 15, 2018
Long-term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factorsGeoffrey Hackett, Nigel Cole, Akhilesh Mulay, et al.
Pageof 6